|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Couraud S, Zalcman G, Milleron B, Morin F
and Souquet PJ: Lung cancer in never smokers: a review. Eur J
Cancer. 48:1299–1311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75 Suppl:191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al WHO Panel, : The 2015 World Health Organization
Classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu
D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage
non-small cell lung cancer and its clinical implication. Cancer
Res. 60:4000–4004. 2000.PubMed/NCBI
|
|
6
|
Yoshida T, Tanaka S, Mogi A, Shitara Y and
Kuwano H: The clinical significance of Cyclin B1 and Wee1
expression in non-small-cell lung cancer. Ann Oncol. 15:252–256.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Daniel C: Lung cancer, a worrying
epidemiological evolution. Rev Infirm. 184:14–16. 2012.(In
French).
|
|
8
|
Ball D, Mitchell A, Giroux D and
Rami-Porta R; IASLC Staging Committee and Participating
Institutions, : Effect of tumor size on prognosis in patients
treated with radical radiotherapy or chemoradiotherapy for
non-small cell lung cancer. An analysis of the staging project
database of the International Association for the Study of Lung
Cancer. J Thorac Oncol. 8:315–321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim JW, Park SJ, Lim JH, Yang JW, Shin JC,
Lee SW, Suh JW and Hwang SB: Triterpenoid saponins isolated from
Platycodon grandiflorum inhibit hepatitis C virus replication. Evid
Based Complement Alternat Med. 2013:5604172013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khan M, Maryam A, Zhang H, Mehmood T and
Ma T: Killing cancer with platycodin D through multiple mechanisms.
J Cell Mol Med. 20:389–402. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim MO, Moon DO, Choi YH, Lee JD, Kim ND
and Kim GY: Platycodin D induces mitotic arrest in vitro, leading
to endoreduplication, inhibition of proliferation and apoptosis in
leukemia cells. Int J Cancer. 122:2674–2681. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou R, Lu Z, Liu K, Guo J, Liu J, Zhou Y,
Yang J, Mi M and Xu H: Platycodin D induces tumor growth arrest by
activating FOXO3a expression in prostate cancer in vitro and in
vivo. Curr Cancer Drug Targets. 14:860–871. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu C, Sun G, Yuan G, Wang R and Sun X:
Effects of platycodin D on proliferation, apoptosis and PI3K/Akt
signal pathway of human glioma U251 cells. Molecules.
19:21411–21423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi YH, Yoo DS, Choi CW, Cha MR, Kim YS,
Lee HS, Lee KR and Ryu SY: Platyconic acid A, a genuine
triterpenoid saponin from the roots of Platycodon grandiflorum.
Molecules. 13:2871–2879. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chun J, Ha IJ and Kim YS:
Antiproliferative and apoptotic activities of triterpenoid saponins
from the roots of Platycodon grandiflorum and their
structure-activity relationships. Planta Med. 79:639–645. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie CQ, Zhou P, Zuo J, Li X, Chen Y and
Chen JW: Triptolide exerts pro-apoptotic and cell cycle arrest
activity on drug-resistant human lung cancer A549/Taxol cells via
modulation of MAPK and PI3K/Akt signaling pathways. Oncol Lett.
12:3586–3590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nachmias B, Ashhab Y and Ben-Yehuda D: The
inhibitor of apoptosis protein family (IAPs): An emerging
therapeutic target in cancer. Semin Cancer Biol. 14:231–243. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Samuel T, Okada K, Hyer M, Welsh K, Zapata
JM and Reed JC: cIAP1 localizes to the nuclear compartment and
modulates the cell cycle. Cancer Res. 65:210–218. 2005.PubMed/NCBI
|
|
20
|
Imoto I, Tsuda H, Hirasawa A, Miura M,
Sakamoto M, Hirohashi S and Inazawa J: Expression of cIAP1, a
target for 11q22 amplification, correlates with resistance of
cervical cancers to radiotherapy. Cancer Res. 62:4860–4866.
2002.PubMed/NCBI
|
|
21
|
Tanimoto T, Tsuda H, Imazeki N, Ohno Y,
Imoto I, Inazawa J and Matsubara O: Nuclear expression of cIAP-1,
an apoptosis inhibiting protein, predicts lymph node metastasis and
poor patient prognosis in head and neck squamous cell carcinomas.
Cancer Lett. 224:141–151. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Che X, Yang D, Zong H, Wang J, Li X, Chen
F, Chen X and Song X: Nuclear cIAP1 overexpression is a tumor
stage- and grade-independent predictor of poor prognosis in human
bladder cancer patients. Urol Oncol. 30:450–456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kishi H, Igawa M, Kikuno N, Yoshino T,
Urakami S and Shiina H: Expression of the survivin gene in prostate
cancer: Correlation with clinicopathological characteristics,
proliferative activity and apoptosis. J Urol. 171:1855–1860. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Docherty AJ, Lyons A, Smith BJ, Wright EM,
Stephens PE, Harris TJ, Murphy G and Reynolds JJ: Sequence of human
tissue inhibitor of metalloproteinases and its identity to
erythroid-potentiating activity. Nature. 318:66–69. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gouyer V, Conti M, Devos P, Zerimech F,
Copin MC, Créme E, Wurtz A, Porte H and Huet G: Tissue inhibitor of
metalloproteinase 1 is an independent predictor of prognosis in
patients with non small cell lung carcinoma who undergo resection
with curative intent. Cancer. 103:1676–1684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aaberg-Jessen C, Christensen K, Offenberg
H, Bartels A, Dreehsen T, Hansen S, Schrøder HD, Brünner N and
Kristensen BW: Low expression of tissue inhibitor of
metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer
patient survival. J Neurooncol. 95:117–128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayakawa T, Yamashita K, Tanzawa K,
Uchijima E and Iwata K: Growth-promoting activity of tissue
inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of
cells. A possible new growth factor in serum. FEBS Lett. 298:29–32.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alao JP: The regulation of cyclin D1
degradation: Roles in cancer development and the potential for
therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Diehl JA: Cycling to cancer with cyclin
D1. Cancer Biol Ther. 1:226–231. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dworakowska D: Clinical significance of
cyclin Dl expression in non-small cell lung cancer. Pneumonol
Alergol Pol. 73:297–300. 2005.(In Polish). PubMed/NCBI
|
|
31
|
Ishii Y, Pirkmaier A, Alvarez JV, Frank
DA, Keselman I, Logothetis D, Mandeli J, O'Connell MJ, Waxman S and
Germain D: Cyclin D1 overexpression and response to bortezomib
treatment in a breast cancer model. J Natl Cancer Inst.
98:1238–1247. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Du WW, Yang W, Liu E, Yang Z, Dhaliwal P
and Yang BB: Foxo3 circular RNA retards cell cycle progression via
forming ternary complexes with p21 and CDK2. Nucleic Acids Res.
44:2846–2858. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hinds PW, Mittnacht S, Dulic V, Arnold A,
Reed SI and Weinberg RA: Regulation of retinoblastoma protein
functions by ectopic expression of human cyclins. Cell.
70:993–1006. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yam CH, Fung TK and Poon RY: Cyclin A in
cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX,
Dai RY, Ren YB, Fu J and Wang HY: The oncoprotein p28GANK
establishes a positive feedback loop in β-catenin signaling. Cell
Res. 21:1248–1261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Neumeister P, Pixley FJ, Xiong Y, Xie H,
Wu K, Ashton A, Cammer M, Chan A, Symons M, Stanley ER, et al:
Cyclin D1 governs adhesion and motility of macrophages. Mol Biol
Cell. 14:2005–2015. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Arber N, Doki Y, Han EK, Sgambato A, Zhou
P, Kim NH, Delohery T, Klein MG, Holt PR and Weinstein IB:
Antisense to cyclin D1 inhibits the growth and tumorigenicity of
human colon cancer cells. Cancer Res. 57:1569–1574. 1997.PubMed/NCBI
|
